Klinika Ambroziak Dermatologia
- Address
- Kosiarzy 9A, 02-953 Warsaw, Poland
Chronic Spontaneous Urticaria Research
Klinika Ambroziak Dermatologia is conducting studies aimed at improving the management of persistent hives by testing a new biologic agent.
- Evaluation of treatment durability over a 52‑week period
- Comparison of active therapy versus placebo in symptom reduction
- Assessment of patient‑reported outcomes and quality of life
The goal is to demonstrate the efficacy of barzolvolimab in achieving sustained disease control for Chronic Spontaneous Urticaria.
Cold‑Induced Urticaria & Symptomatic Dermographism Studies
Research at the Warsaw site focuses on allergic skin reactions triggered by cold exposure and physical stimuli, seeking effective therapeutic options.
- Provocation testing to measure complete response at Week 12
- Investigation of rapid symptom relief after treatment initiation
- Monitoring of adverse events to ensure safety
These trials aim to confirm that barzolvolimab can significantly improve outcomes for patients with Cold‑Induced Urticaria and Symptomatic Dermographism.
Long‑Term Efficacy and Safety Extension
An extension study follows participants beyond the initial trial to gather data on lasting benefits and tolerability of the investigational drug.
- Tracking time to disease worsening or treatment failure
- Longitudinal safety monitoring throughout the extension period
- Evaluation of continued clinical response in real‑world settings
The extension seeks to provide robust evidence that barzolvolimab remains effective and safe for long‑term use in chronic urticaria conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Celldex Therapeutics Inc.2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celldex Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinika Ambroziak Dermatologia
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Barzolvolimab in Participants with Cold-Induced Urticaria and Symptomatic Dermographism | Celldex Therapeutics Inc. | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 2 | Unknown | 2026-04-13 | 2026-04-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.